CDR-404 is under clinical development by CDR-Life and currently in Phase I for Squamous Non-Small Cell Lung Cancer. According to GlobalData, Phase I drugs for Squamous Non-Small Cell Lung Cancer have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CDR-404’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CDR-404 overview
CDR-404 is under development for the treatment of solid tumors, bladder cancer, synovial sarcoma, head and neck squamous cell carcinoma and non-small cell lung cancer, squamous non-small cell lung cancer. It is administered through intravenous route. The drug candidate is a bi-specific antibody targeting melanoma associated antigen 4 (MAGE A4). It is a new biological entity being developed based on M-gager technology.
The drug candidate was under development for the treatment of melanoma and esophageal cancer.
CDR-Life overview
CDR-Life is a biotechnology company that develops tumor-targeted immunotherapies. Its pipeline products include CDR202 which treats macular degeneration; CDR101 for multiple myeloma; CDR404, CDR505, CDR304, CDR813, CDR208, CDR905, CDR609 targets solid tumors. The company uses M-gager, an antibody platform which delivers a modular technology with unparalleled tumor antigen specificity, allowing selective targeting of tumor cells while sparing healthy tissues. It collaborates with pharma and biotech companies to bring new therapeutics to market. CDR-Life is headquartered in Horgen, Zurich, Switzerland.
For a complete picture of CDR-404’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
